(19) World Intellectual Property Organization International Bureau





(43) International Publication Date 17 October 2002 (17.10.2002)

PCT

(10) International Publication Number WO 02/080708 A2

(51) International Patent Classification?:

A24F

(21) International Application Number: PCT/IB02/01112

(22) International Filing Date: 9 April 2002 (09.04.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

2001/2893 9 April 2001 (09.04.2001) ZA 2001/4060 18 May 2001 (18.05.2001) ZA

(71) Applicant and

(72) Inventor: ENSLIN, George, Frederick [ZA/ZA]; 6 Waldorf Drive, Centurion Golf Estate, 0002 Centurion (ZA).

(74) Agent: FORBES, Craig, Paul; Adams & Adams, Adams & Adams Place, 1140 Prospect Street, Hatfield, PO Box 1014, 0001 Pretoria (ZA).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

 without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



2/080708 A2

(54) Title: A SMOKER'S REQUISITE

(57) Abstract: A smoker's requisite embodies a substance selected from pharmaceutical products, food supplements, natural products and combinations thereof. The substance is embodied in the requisite such that, when the requisite is lit and smoked by a smoker, a quantity of the substance is ingested by the smoker.

5

10

15

20

A SMOKER'S REQUISITE

THIS INVENTION relates to a smoker's requisite.

For the purposes of this specification, a "smoker's requisite" should be understood to mean an object or device such as a cigarette or pipe which is lit and smoked by a smoker and accordingly includes, without being limited thereto, plain and filter cigarettes, pipes, cigars, cheroots and the like and the term further includes within the scope of its meaning a "smoking accessory" by which is meant an object or device which is used together with a cigarette, pipe, cigar, cheroot or the like such as a filter, cigarette holder, cigar holder or the like.

According to a first aspect of the invention there is provided a smoker's requisite which embodies a substance selected from pharmaceutical products, food supplements, natural products and combinations thereof, the substance being embodied in the requisite such that, when the requisite is lit and smoked by a smoker, a quantity of the substance is ingested by the smoker.

The substance or composition may be embodied in a component from which a smoker's requisite is made.

For example, it may be mixed with or impregnated into the tobacco of the smoker's requisite such as a cigarette or cigar prior to the manufacture of the requisite. It may be mixed with or impregnated into pipe tobacco or chewing tobacco. The substance may be crystallized or ground into a powder, dissolved or liquified prior to being mixed with or impregnated into the tobacco. A portion of a plant or a substance of the invention may be desiccated, ground, shredded or reduced to smaller particles and these particles may be incorporated into the requisite. Instead, the

2

substance or composition may be impregnated into the paper of a cigarette or into a filter of a cigarette, cigar, pipe or the like.

5

10

15

20

25

The tobacco, filter or cigarette paper may be impregnated with the substance or composition by methods such as applying the substance in liquid form to the tobacco, filter or cigarette paper, by immersing the tobacco, filter, or cigarette paper in a solution of the substance, impregnating by pressure, chemically impregnating, using an adhesive, saturation, gaseous infusion, immersion, spraying, radiation, osmosis, friction, mixing, blending, infusion, coating or waxing. The substance or composition may be carried or cased in animal or plant fats or modifications of them such as tallow, palm butter, cocoa butter, synthetic fats, saccharides such as lactose, glucose or mannose or in polymers or polymeric substances such as gelatine, cellulose, polyethyleneglycol and polyvinyl alcohol. Alternatively it may be placed in or combined with calcium salts, waxes, paper, hemp, sisal, twine, water soluble materials. It may be in a membrane, sponge, sponge type matrix, porous or pumice type structure which may be rigid or flexible, porous or impervious.

In another embodiment of the invention, the particles are impregnated into the paper of the requisite by chemical impregnation using a dry or liquid chemical impregnation either during the manufacturing of the paper or during the manufacture of the requisite. For example, the substances or particles may be incorporated by mixing or blending the particles into a liquid or dry mix, which is then mixed into the pulp from which the paper or the constituents including the filter of the requisite are manufactured. Impregnation may be by soaking the paper or filter in a liquid containing the substances or extracts of the substances. Impregnation may be achieved through bonding the required substance or portions of the substance or ground or desiccated particles of the substance to the paper or filter of the requisite. This method includes bonding by pressure or the use of adhesives or bonding agents. Impregnation can also be achieved by spraying.

3

In other embodiments, similar methods are used to apply the substance or composition to cigar leaves.

The substance may be rolled into a filter, or form part of the filter paper or be impregnated into the filter paper. In an embodiment of the invention, the substance itself forms a filter or a part of a filter. For example, where the substance is a natural product which occurs in a plant, the filter may be constructed entirely or in part using material from the plant such as its leaf. The leaf may be used in its whole form or shredded and then shaped into a cigarette filter. The construction of the filter may then be similar to that of a conventional cigarette filter. In an embodiment of the invention the filter may be constructed entirely from the plant material or the plant material may be encased in an outer paper sheath in conventional fashion. For example, tealeaves such as green tealeaves may be rolled into a filter or may be used to make a filter.

5

10

15

20

25

In an embodiment of the invention, the substance or composition is sandwiched between the filter of a cigarette and the tobacco of the cigarette.

In another embodiment of the invention a carrier which carries the pharmaceutical products, food supplements, natural products or combinations thereof is incorporated or embodied in the smoker's requisite or smoking accessory. The carrier may be in the form of a cartridge, pill, package, membrane or screen which carries the substance and it may be located at any suitable position in the requisite or accessory.

For example, the cartridge or membrane may be located before, after, or in the filter. It may be placed in a smoker's requisite such as a cigarette at either end or at any point along the body of the requisite. The carrier may be refillable or rechargeable for multiple use or disposable.

The act of smoking will then cause at least some of the substance or composition to be carried with the smoke into the mouth, throat and/or lungs of the smoker and thereby cause the substance or composition to be ingested by the smoker.

WO 02/080708

The invention accordingly extends to a smoker's requisite or accessory which includes a component selected from one or more of tobacco, paper, a filter and a carrier, with a substance as described below embodied in the tobacco, paper, filter or cartridge.

5

It extends further to a smoker's requisite which includes a filter and in which the filter is formed from a substance as hereinbefore described.

anti-pyretics, anti-carcinogenic and chemo preventive agents, anti-oxidants,

The substance or composition may be selected from flavanols, anelgesics,

10

15

anxiolytics, angiogenisis inhibitors, anti-aging substances, antibiotics, antihistimines and anti-allergenics, anti-hypertensive agents, anti-inflammatories, memory and brain function treatment agents, cardiovascular and circulatory agents, diabetes treatments, anti-hypercholesterolaemics, immune system enhancers, immunizing agents, minerals, respiratory agents, sedatives, anti-stress agents, aphrodisiacs, sexual disfunction agents, enhancement drugs, tonics, stimulants and vitamins, anti-metabolites, nitrosoureas, tryptamine derivatives, proteins, steroids, vitamins and provitamins, statins, sulphonamides, substituted indoles, substituted imidazoles, metal-containing compounds, drug substances, anti-depressants, immunosuppressants, hormones, antibiotics, phytochemicals, and mixtures of any two or more thereof. Where the substance or composition comprises a mixture e.g. a mixture of natural products, such as a mixture of polyphenols, the substance or composition may comprise a portion or a combination of portions of such mixtures or a combination of such portion or portions with any of the other substances or

20

compositions.

Where a natural substance such as a herb, plant or the like is used, the word "substance" refers to the natural or unrefined substance itself or to a partially or fully refined product produced, distilled, extracted or reduced from the substance.

25

The alkylating agent may be selected from alkyl sulphonates, ethyleneimine compounds and other alkylating agents. The N-mustard may, for

5

example, be selected from chlorambucil, cyclophosphamide, melphalan, mustine and pipobroman. The alkyl sulphonate may be selected from busulphan and treosulfan. The ethyleneimine compound may be thiotepa. The alkylating agent may instead be selected from hexamethylmelamine, mitobronitol, mutolacetol and ethoglucid.

The substance may be selected from catechin, gallic acid, epigallocatechin gallate, epigallocatechin, epicatechin, epicatechin-3-gallate, epicatechin gallate, epigallocatechin-3-gallate. The tryptamine derivative may be selected from serotonin and melatonin. The protein may be selected from endostatin and angiostatin. The steroid may be selected from steroidal anti-inflammatories. It may for example be an estrogen or estrogen metabolite such as 2-methoxyestradiol.

5

10

15

20

25

The substance may be selected from tocopherol, alpha-tocopherol, betacarotene, retinoic acid and ascorbic acid. The statins and compactins may be selected from lovastatin, simvastatin and pravastatin. The sulphonamide may be nimesulide. The substituted indole may be Lodine (etodolac). The metal-containing compound may be a selenium compound.

The natural product may be selected from lycopene, caffeine, prenyl flavonoids, Camelia sinensis and rosemary. The natural product may be of the type found in food and beverages such as the vegetables alfalfa, onions, spinach, broccoli, kale, garlic, red bell peppers and beets, fruits including bananas, red and white grapes, oranges, strawberries, kiwi fruit, grapefruit, pink grapefruit and their seeds, tomato and apple and beverages including teas from Camelia sinensis, apple juice, grape juice, red wine, tomato and orange, and cocoa. It may be plant substance such as Echinacea, ambrosia marijuana/cannabis/hemp or alfalfa. It may be plant material, for example plant material in its natural state from a plant having anti-carcinogenic or other medicinal properties.

The pharmaceutical product may be selected from anti-carcinogenic substances such as traodone, interferon, thalidomide, CoI-3, tamoxifen, COX-2 inhibitors, celebrex, rofecoxib (vioxx), imatinib mesylate (gleevec) (STI 571),

WO 02/080708

5

10

15

20

25

cyproheptadine, aspirin and paracetamol. Cyproheptadine is used as an adjunct to radiotherapy and the use of cyproheptadine may be advantageous in radiotherapy. Dosages of 200 - 300 mg or more of the targeted approach drugs such as C225 which is normally administered intravenously and the molecularly targeted drug such as gleeved result in blood counts in leukemia sufferers returning to normal with minimum side effects.

The anti-depressant may be selected from monoamine oxidase inhibitors such as the hydrazine derivatives, isocarboxazid, phenelzine, nialamide, iproniazid and mebanzine as well as the non-hydrazine monoamine oxidase inhibitors such as pargyline, the tricyclic anti-depressants such as dibenzazepine or zocyclohepetene derivatives such as amitriptyline, butriptyline, desipramine, clomipramine, protriptyline, nortriptyline, opipramol as well as trimipramine and iprindole which have different cyclic structures, and the tetracyclics maprotiline and mianserin.

The flavonoid may be a prenyl flavonoid of the type found in hops and beer i.e. chalcones from hops as well as prenylchalcones and prenylflavonones from naringeninand 2-hydroxy-2-methylbut-3-ene or linalool and xanthohumol from the prenylchalcone in beer.

The food supplement may be a mineral supplement such as a calcium supplement, a vitamin, tonic or stimulant.

The substance or composition may, instead, be a peroxide such as hydrogen peroxide or a synthetic anti-oxidant. The substance or composition may be a natural anti-carcinogen

catsclaw, olive leaf (as well as the extract of olive leaf and olive leaf concentrate), paud'arco, mistletoe (also sold as iscar and iscador) or cartilage including shark cartilage.

The substance may be selected from the substances and formulations set out in Tables 1 and 2. The amounts of the substance or substances embodied in a smoker's requisite or smoking accessory may be between the lower value as set out in column A of Table 1 and the higher value as set in column C of Table 1 or the amount set out in column C of Table 2. More particularly, the amounts may be as set out in column A of Table 1. Preferred amounts are set out in column B of Table 1 or column D of Table 2. Column C also represents the maximum and minimum daily dose of the relevant substance.

5

10

15

20

25

30

The invention extends to a carrier which is shaped and dimensioned to be received in a smoker's requisite or accessory selected from cigarettes, cigars, cigarette holders, cigar holders and removable filters which incorporates a substance selected from pharmaceutical products, food supplements, natural products and combinations thereof, the substance being incorporated in the requisite such that, when the requisite is lit and smoked by a smoker, a quantity of the substance is ingested by the smoker.

The carrier may be a package, cartridge, pill, sponge, matrix, filter, porous membrane, tablet or string and may have any suitable shape. It may for example be cylindrical, round, rectangular, square, spherical, tubular or coin shaped. It may be manufactured as a polymeric tube and may be porous, impervious flexible or rigid. It may be a porous or perforated tube which may extend axially down the centre of a cigarette.

The substance may be incorporated into the requisite by manufacturing and configuring it in the form of a string and may be placed or inserted into the requisite or placed on the outside of the requisite. The substance may be impregnated into the string by various methods including use of adhesives, bonding agents, or by soaking, gaseous infusion, immersion, spraying, friction, glueing, impregnation by pressure, sealing, coating or waxing. The string, containing the required substance or plant, may contain binding materials or inert materials to hold or bind the substances together in the form of a string. If the substance to be incorporated is in dry powder,

crystalline or granular form the string may be coated with a coating such as wax or fat such as bees wax or cocoa butter to bond the substance or powder. Alternatively, the string may be manufactured partially or wholly from or with the substance to be incorporated into the smoker's requisite.

8

The carrier provides insulation of the substance and protects it from oxidation, or destruction and to regulate the heat so as to regulate and control release of the substance (i.e. quantity and timing). This string may be stored or coiled into rolls from which lengths as required may be placed into the smoker's requisite at the time

of manufacture of the smoker's requisite. Instead, the substance may be impregnated

into or embodied in a prior made string. The substance may, instead, be embodied

in a band of paper or similar material.

10

15

20

25

The bands may be applied onto or wrapped around the requisite or may be formed in the paper as an integral part of the paper from which the cigarette is manufactured. The required substance is then carried by the paper and forms an integral part of the cigarette paper. The incorporation or manufacture of the various bands may be done at the time of manufacture of the cigarette paper. These bands may be applied in ring form around the diameter of the smoker's requisite e.g. a cigarette or cigar in lengths which may be straight or otherwise along the length of the cigarette. These bands may also be applied to the cigarette in various patterns including coiled, spiral, in wave form along the length of the cigarette, in zigzag pattern and various other patterns.

The invention extends further to a smoking accessory selected from cigarette holders, cigar holders and detachable filters which incorporates a substance selected from pharmaceutical products, food supplements, natural products and combinations thereof.

It extends further to a method of making a smoker's requisite which embodies a substance selected from pharmaceutical products, food supplements, natural products and combinations thereof, which includes combining a component of

9

a smoker's requisite with the substance and using the component to make the requisite.

The invention extends, further, to a method of administering to a person a substance selected from pharmaceutical products, food supplements, natural products and combinations thereof which includes the step of incorporating the substance in a smoker's requisite as hereinbefore described so that, when the smoker's requisite is smoked by a person, an amount of the substance or composition is ingested by the person during smoking.

The invention extends further to a method of administering to a person a substance selected from pharmaceutical products, food supplements, natural products and combinations thereof which includes the step of incorporating the substance in a smoking accessory as hereinbefore described so that, when the smoking accessory is used together with a smoker's requisite, an amount of the substance is ingested by the person during smoking.

15

20

25

10

5

According to another aspect of the invention, there is provided a method of making a smoker's requisite which embodies a substance selected from pharmaceutical products, food supplements, natural products and combinations thereof, which includes incorporating a carrier which carries the substance in the smoker's requisite so that when the requisite is lit and smoked by a smoker, a quantity of the substance is ingested by the smoker.

The substance may be a combination of one or more of the pharmaceutical products, food supplements and natural products.

In preferred embodiments of the invention the substance or composition comprises, in combination, novastatin and Lodine or in combination a statin such as mevacor (Iovastatin) and a COX-2 inhibitor such as celebrex, vioxx or nimesulide or in combination mevacor (Iovastatin) and Lodine XL. In another preferred embodiment of the invention the substance or composition comprises mycopene, a selenium

10

compound and green tea. In another preferred embodiment the substance or composition comprises epigallocatechin-3-gallate, epigallocatechin, epicatechin gallate and/or epicatechin-3-gallate. In another preferred embodiment the substance or composition is a combination of epigallocatechin gallate and curcumin. A combination of catechins is better than epigallocatechin gallate alone for producing cell apoptosis. The effect is synergistically increased when catechins are combined with other anticarcinogenic substances such as tamoxifen. In another preferred embodiment a seratonin antagonist such as periactin (cyproheptadine) can be used alone or in conjunction with melatonin. A dosage of 36 mg of melatonin daily as an adjuvant in conjunction with traditional cancer treatments reduces the side effects of toxic therapies and increases their effectiveness.

An anti-carcinogenic substance, for the purposes of this specification, is a substance which acts against cancer in a prophylactic fashion or is a substance which can be used in the treatment of cancer, for example in a chemotherapeutic fashion.

The smoking of a smoker's requisite or the use of a smoking accessory as hereinbefore described incorporating extracts of Camelia sinensis results in the ingestion of epigallocatechin gallate. This compound has been shown to be active amongst others against colon cancer, melanoma, breast cancer and lung cancer.

20

5

10

15

In order to inhale and ingest the various compounds and substances of the invention, certain of these have to be broken down, diffused or vapourised so that they can be transported into the draught or flow of air and smoke being drawn in by the smoker or diffused and released into the atmosphere where it could be breathed by a passive smoker.

25

Heat generated by the glowing end of a cigarette, will gradually permeate along the length of the cigarette. The resulting increase in temperature, depending upon the substance or composition used, will allow or cause the substance or composition to be progressively released and inhaled by the smoker. Different

11

substances will be released at different temperatures. The end of a cigarette which is closest to the user when being smoked will initially be cooler than the opposite end and will gradually increase in temperature as the cigarette is smoked. The release of the substances is optimised by the positioning of the substances in the requisite. With certain substances that are more sensitive to heat or require only a small amount of heat to release them or their required active ingredient, the substance is placed at the end of the requisite closest to the smoker's mouth. At this end, the substance is not immediately subjected to the extreme heat generated at the lit end. This preserves the integrity of the substance for a longer period. The substance is then subjected to a gradual increase in temperature as the lit end approaches the area where the substance has been placed. The rise in temperature and/or the air drawn through the cigarette causes the active ingredients to be released. The constituents so released are then be ingested by the person smoking the requisite.

5

10

15

20

25

The substance or composition may be placed along the length of the cigarette or at any point where it will reach the optimal temperature for the optimal period of time. This would be predetermined before manufacture by taking into account which substance is to be used and may be determined by routine experimentation.

The cigarette or cigar holder may be openable by a flip, screw, bayonet taper or push-in mechanism and an anti-carcinogenic package, food supplement package, medication package or anti-depressant package, filter or membrane may be receivable in the accessory. The holder may be attachable to a cigarette or cigar by a push, taper or friction fit.

The invention extends to an anti-carcinogenic cartridge which can be inserted into a cigarette holder, cigar holder or pipe.

For purposes of this specification the words "substance" and "material" include any compound, mixture, blend, medication, formula, drug (synthetic or natural), hormone, plant, seed, pollen, flower, vegetable, fruit or bio-organism and

WO 02/080708

PCT/IB02/01112

12

includes the above in their natural, organic or synthetic form or a derivative or modification of any of them and when used in their whole, part, refined or unrefined form or only a portion or any constituent of, extract, fraction, molecule or distillate derived from any of the above or a portion of the aforegoing (extract) in its refined or unrefined form or a synthetically manufactured derivative or substitute of any of the aforegoing. Any of these may be used individually or in combination with each other or with other remedies, formulae or substances.

The mass and bulk of some of the formulae of this invention require that the formulation be carried in a cartridge which is inserted into a filter which is detachable from the cigarette. The detachable filter may be pre-packed with a substance of medication and may be in the form of a disposable single use filter or it may be used until the medication or substance is depleted. Alternatively the filter may be in a form where it may be re-used in which instance a fresh cartridge/carrier is inserted.

15

10

5

The filter is pushed onto the end of the requisite which may be filterless or already have a filter and may be held in place by a ringed sleeve which can be rigid or flexible.

The medication may then be incorporated into the filter by one of the methods described above or by the insertion of the "carrier".

20

25

The medication can also be incorporated by the insertion of a porous membrane which carries the medication.

A non-porous membrane may be used behind which the medication is packed or stored. The medication may be sandwiched between two membranes or between a membrane and the tobacco portion of the requisite. Alternatively the medication may be carried or housed in a cartridge through which the smoke from the burning tobacco can pass. The cartridge may have a porous or non-porous membrane on one or both sides through which the smoke can pass.

13

The cartridge or carrier may be made from porous paper, material, or cellulose. When the detachable filter is forced onto the end of the requisite the membrane is pierced and the medication is exposed to the draught/flow or air which passes from the lit end of the requisite to the smokers mouth. The non-porous membrane may also be impregnated with a medication.

5

10

15

20

25

The cartridge or insert which is incorporated in the smoker's requisite or accessory protects the integrity of the active ingredients incorporated into the requisite or accessory both during the time the requisite is in storage and during the time it is being consumed and can reduce the temperature to which the substance is exposed during the smoking of the requisite and further allow for the pre-positioning of the substance within the requisite so that the timing of the release and the amount of the substance may be predetermined and controlled. The use of a cartridge or insert to incorporate any particular substance in a smoker's requisite allows easier incorporation of the substance during the manufacturing process. The use of a cartridge or insert allows easier substitution of alternate substances or medications to be incorporated into a requisite without major changes to the manufacturing process when a change of the substance is required.

To regulate the amount of active ingredient or substance released during the smoking of the requisite, the cartridge or insert may be rigid or flexible and may be porous. The degree of porosity may also be varied to determine the amount of air or smoke which passes through it. The draught of air or smoke passing through the insert or cartridge assisted by the heat, releases the active ingredient of the substance in the cartridge.

In addition to air or smoke passing through a selected substance or cartridge or insert, the active ingredients may be dispensed or released by air, smoke or heat passing over or around the substance, the cartridge or insert.

5

10

15

20

25

Alternatively the active ingredients can be released or diffused at the time that the cartridge or insert heats up or is burnt. When using this method the cartridge or insert may be of a non-porous or semi-porous nature.

More than one cartridge may be incorporated into a smoker's requisite. The content, make up and construction of the various cartridges may differ from each other and more than one type of cartridge or insert may be incorporated into a smoker's requisite.

The insert or cartridge carries the substance and dispenses or infuses the substance into the requisite either before or during the igniting and combustion of the smoker's requisite. Such infusion or dispensing into the requisite can be achieved by way of diffusion. The cartridge or insert may also be manufactured from a porous material or a porous membrane so that the substance can diffuse through the walls of the cartridge or insert. Alternatively dispensing or diffusion can be achieved by holes or perforations in the cartridge or insert.

The dosage or amount of substance delivered to the smoker can be varied by increasing or decreasing the quantity and size of cartridges incorporated into the requisite or increasing or decreasing the amount of string incorporated into the requisite or by varying the porosity of the insert or cartridge or by increasing the number or size or perforations in the insert or cartridge.

Instead the substance may be placed at any point in the requisite. The substance may be housed in a cavity or pocket anywhere in the requisite or in a cavity or pocket sandwiched between the filter and the section of the requisite containing the tobacco or within a cavity or pocket either in the tobacco portion or filter portion of the requisite or combined in the paper or glue.

In another embodiment of the invention, the substance in a desiccated, shredded or ground state may be blended into an inert carrier, which is then placed into the requisite or filter. The inert carrier, which encases the substance is selected

so as to release the substance or the active material from the substance at a predetermined temperature and to protect the integrity of the substance from excessive heat until it can be ingested or inhaled by the smoker.

Another method of incorporation is to fold or roll the particles into the filter at the time of manufacture of the filter.

5

10

15

20

Another method of incorporation is to blend or mix the particles into the tobacco mix.

In yet another embodiment, the substance is incorporated into the filter of the requisite. The substance may be incorporated by rolling, folding or impregnating it into the filter or filter paper.

In yet another embodiment the *Camellia sinensis* or rosemary plant or certain of the constituents of the *Camellia sinensis* or rosemary plant or a combination of the plants may be incorporated into the body of the requisite where the tobacco is housed or used as described above.

In yet another embodiment, the process and method used in the manufacture of a conventional cigarette filter is employed using material selected from a plant.

In yet another embodiment the plant material may be incorporated into a filter made from the materials and according to the process employed in the manufacture of a conventional cigarette filter.

In yet another embodiment portions of the plant material are placed in a porous cartridge which is then incorporated into the smoker's requisite.

Naturally, more than one of the substances can be used in a single smoker's requisite or accessory.

16

The invention is now described, by way of example, with reference to the following Examples.

EXAMPLE 1

Mevacor (Iovastatin) and Lodine XL were combined with cigarette tobacco and formed into a cigarette. The amount of Mevacor (Iovastatin) incorporated was 50 mg and the amount of Lodine XL was 4 mg. The preferred daily dosage of Iovastatin is 1000 mg and that of Lodine XL 80 mg per day.

5

10

15

EXAMPLE 2

Cyproheptadine was mixed with cigarette tobacco and the tobacco was formed into a cigarette. The amount of cyproheptadine incorporated was 0,2 mg. The preferred daily dosage of Cyproheptadine is 4 mg. The daily intake of Cyproheptadine may vary between 4 – 12 mg.

EXAMPLE 3

Melatonin was mixed with cigarette tobacco and the tobacco was formed into a cigarette. The amount of melatonin incorporated was 1,8 mg. The preferred daily dosage of melatonin is 36 mg. The daily intake of melatonin may vary between 3 – 200 mg.

EXAMPLE 4

Tamoxifen was mixed with cigarette tobacco and the tobacco was formed into a cigarette. The amount of tamoxifen incorporated was 1mg. The preferred daily dosage of tamoxifen is 20 mg. The daily intake of tamoxifen may vary between 10 – 40 mg.

EXAMPLE 5

A formulation consisting of 1,8 mg of Melatonin and 0,2 mg Cyproheptadine was mixed with cigarette tobacco and the tobacco was formed into a cigarette.

EXAMPLE 6

5 Cyproheptadine was mixed with cigarette tobacco and the tobacco was formed into a cigarette. The amount of cyproheptadine was selected so that, by smoking a predetermined number of cigarettes per day, a dose of 4 mg of the cyproheptadine was delivered to a smoker.

EXAMPLE 7

Flavonols were mixed with cigarette tobacco and the tobacco was formed into a cigarette. The amount of flavanols incorporated was 25mg. The preferred daily dosage of flavanols is 20 mg. The daily intake of flavonols may vary between 10 – 1000 mg.

EXAMPLE 8

Endostatin was mixed with cigarette tobacco and the tobacco was formed into a cigarette. The amount of endostatin incorporated was 15 mg. The preferred daily dosage of endostatin is 300 mg. The daily intake of indostatin may vary between 3,75 - 600 mg.

20 EXAMPLE 9

Melatonin and Cyproheptadine were combined with cigarette tobacco and formed into a cigarette. The amount of Melatonin incorporated was 1,8mg and the amount of Cyproheptadine was 0,2 mg. The preferred daily dosage of malatonin is 36 mg and

5

10

15

PCT/IB02/01112

that of Cyproheptadine is 4mg per day. The daily intake of Melatonin may vary between 3 - 200 mg per day and that of Cyproheptadine 4 - 12 mg per day.

EXAMPLE 10

The procedure of Examples 1 and 2 was followed but the active ingredients were impregnated into the paper of the cigarette.

EXAMPLE 11

Plant material extracted from the *Camellia sinensis* and rosemary plant were cut, blended and rolled into the form of a string. An inert tasteless binding agent was used to hold the string together. This string was coiled onto a core or spindle for storage and ease of handling. From this coil a length was cut and inserted into a cigarette at the time of manufacture. In use, when the cigarette was smoked, the string burned gradually down the length of the cigarette. The plant material gradually released its active ingredients as the string burned. The string was subjected to an increasing temperature from ambient gradually rising along the length of the string as the burning end of the cigarette proceeded down the length of the cigarette. The progressive increase in temperature allowed the string to release its active components. The components were ingested by the smoker by inhalation.

EXAMPLE 12

Example 11 was repeated but instead of arranging the string linearly along the length of the cigarette it was coiled cylindrically along the cigarette close to the outer paper. In this embodiment the dosage and delivery of the active ingredient was increased as more string containing the active ingredient was incorporated into the cigarette than was incorporated in Example 4.

19

EXAMPLE 13

Example 11 was repeated but the string was coiled in a smaller diameter coil down the approximate centre line of the cigarette along its length.

EXAMPLE 14

Example 11 was repeated and in this case a tightly compressed coil of string configured in the shape of a watch spring but more tightly wound was incorporated and sandwiched between the filter and tobacco of the requisite.

10

15

20

25

EXAMPLE 15

Example 11 was repeated several more times and active ingredient in each example was varied by altering the configuration in which the string was incorporated into the requisite. When the string was tightly coiled with the coils being closely spaced to each other, the amount of string in relation to the length of the requisite was increased resulting in a higher concentration of active ingredient per length of requisite. The dosage and delivery rate was altered by either using a loosely wound spaced coil, which resulted in a lower concentration of active ingredient per length of requisite or a tightly wound spaced coil which provided a higher concentration and consequently a higher dosage. To obtain variation in the amount of active ingredient delivered the string was incorporated into the cigarette in various configurations including coiling, zigzagging, straight lengths, wave pattern, rings, individual rings, linked rings, joined looped rings, U-shape, linked U-shape patterns as well as watch spring and Catherine Wheel type patterns.

In one embodiment, the string coil was wound on the outside of the cigarette along its length. In another embodiment, a tightly compressed coil was placed in the filter section of the cigarette. In another embodiment, more than one coil was used and interspersed through the filter of the cigarette. In another embodiment, the coil was placed in the tobacco section of the cigarette. In another embodiment, more than

20

one coil was used and these were placed in the filter section as well as the tobacco section of the cigarette. In another embodiment, more than one coil was used and these were placed in the filter section as well as the tobacco section of the cigarette.

5 EXAMPLE 16

1000mg of the analgesic Paracetamol in powder form was encased in a porous cylindrical hollow barrel type cartridge which was then placed longitudinally into a cigarette.

EXAMPLE 17

A porous cartridge was manufactured in which a mix of Epigallocatechin gallate (25mg) and curcumim (37,5mg) were placed. This was incorporated in a cigarette directly in front of the filter so that it was sandwiched between the filter and the tobacco of the cigarette.

EXAMPLE 18

Example 10 was repeated and the cartridge was placed in the filter portion of the cigarette.

EXAMPLE 19

A filter for a cigarette was manufactured in which a mixture of Epigallocatechin gallate (25mg) and curcumin (37,5mg) from turmeric was impregnated into the filter material. This filter was then used in the manufacture of a smoker's cigarette.

EXAMPLE 20

A filter for a cigarette was manufactured using parts of the *Camellia sinensis* plant and incorporating these into the filter by rolling and folding strips and portions of the plant into the filter paper.

5

40

15

EXAMPLE 21

Example 20 was repeated four more times with the following changes.

In one embodiment, the plant material was ground and lodged in the filter during the manufacture of the filter.

In another embodiment, the constituent parts of the *Camellia sinensis* plant were bonded to the filter paper prior to the manufacture of the filter.

In another embodiment, the constituent parts were made to adhere to the filter paper by using pressure to impress these into the paper.

In another embodiment, the constituents of the *Camellia sinensis* plant were bonded to the filter paper using bonding material which would not adversely affect the taste of the cigarette when this was smoked.

EXAMPLE 22

A filter was constructed using large unrefined sections of the *Camellia sinensis* plant which were processed and rolled to form a filter.

EXAMPLE 23

20 Example 22 was repeated but the *Camellia sinensis* plant was shredded into smaller sections, before being rolled into the shape of a filter.

22

EXAMPLE 24

Example 22 was repeated using shredded sections of the Camellia sinensis plant.

EXAMPLE 25

A cigarette was made using a blend of shredded *Camellia sinensis* plant and tobacco.

5

10

EXAMPLE 26

Plant material selected from the plant materials of the invention were finely ground and then compacted and tightly packed in a porous cartridge which was then incorporated into a cigarette directly in front of the filter. This cartridge was held in place by being sandwiched between the filter and the tobacco of the requisite.

EXAMPLE 27

Example 26 was repeated several times but the cartridges were placed at various points within the length of the tobacco portion of the cigarette.

EXAMPLE 28

Example 26 was repeated but the cartridge was placed in the filter.

EXAMPLE 29

Example 26 was repeated but more than one cartridge was placed in the tobacco section and in the filter of the cigarette.

5

10

15

20

EXAMPLE 30

23

Pulp from grapefruit was desiccated and ground to around 60/100 mesh. Seeds from the grapefruit were dried and ground to around 60/100 mesh. The pulp and seed particles were blended and 50 ml of this blend was mixed into a tobacco mix from which a cigarette was manufactured. This provides protection for humans against mosquito and mosquito related diseases such as malaria.

EXAMPLE 31

In further embodiments, the blend was impregnated into the filter or the cigarette paper or incorporated into a string and used as in Examples 4-8 or incorporated into a porous cartridge and used as in Examples 20-23.

EXAMPLE 32

Pulp from grapefruit was desiccated and ground to around 60/100 mesh. Seeds from the grapefruit were dried and ground to around 60/100 mesh. The pulp and seed particles were blended and 50 mg of this blend was added to 55 mg of artemisia annua and 10 mg of berberine. This mix was mixed into tobacco from which a cigarette was manufactured.

EXAMPLE 33

Examples 11-29 were repeated using the blend of Example 33.

It is an advantage of the invention illustrated that, in the case of a person who is smoking or addicted to smoking, the incorporation of an anti-carcinogenic compound in a cigarette, or in pipe tobacco or the like should serve to reduce or possibly prevent the incidence of cancer which can be caused through smoking. It is also an advantage of the invention illustrated that, where a person has contracted, for example, lung cancer through smoking but nevertheless refuses

24

to stop smoking, the method of the invention can be used to dose the person with a chemotherapeutic agent to treat the cancer. It is also an advantage of the invention illustrated that the invention may be used to provide nutrition, food supplements, drugs, vitamins, remedies or medications to a smoker who may not have cancer.

5

Q		500 mg	60 mg	500 mg	100 mg	1160 mg	100 mcg	100 mg	100 mg	500 mg	100 mg	800,1 mg
O					To the state of th	116 – 1740 mg				The state of the s	The state of the s	80 – 1200,15 mg
ന		The fact that the second secon		The state of the s		58 mg		The state of the s		To the state of th		40,0 mg
A		THE CONTRACT OF THE CONTRACT O		And the second s		0,058 – 87 mg				A PROPERTY OF THE PARTY OF THE		4 – 60 mg
Name / Substance /	Compound / Active Ingredient	Methylsulphonylmethane (MSM)	Pycnogenal	Epigallocatechin gallate (EGCg)	D-alpha tocopheryl succinate		Selenium	Pine bark extract	Grapeseed extract	Epigallocatechin gallate (EGCg)	D-alpha tocopheryl succinate	
		FORMULA					FORMULA					

ABLE 1

15 mg	0,025 mg	0,1 mg	0,02 mg	10 mg	10 mg	500 mg	60 mg	595,14 mg		1,50	300 mg		1 .	300 mg		
				100 000 000 000 000 000 000 000 000 000				59,51 - 892,71	mg	1-49	100 – 700 mg		1-39			
								29,7 mg		75 mg	15 mg		50 mg			
		The state of the s						2,98 – 44,64 mg		50 ~ 200 mg	5 – 35 mg		50 – 150 mg			
Beta carotene	Cryptoxanthin	Alpha carotene	Zeaxanthin	Lutein	Lycopene	Epigallocatechin gallate (EGCg)	Vaccinium myrtillus			Gamma-Aminobutyric Acid	Piper methysticum	Standardized Extract (30% - 70% kavalactones)	Scutellaria lateriflora	Piper methysticum	Standardized Extract (30% - 70%	kavalactones)
FORMULA	October 1997 Control of the Control													FORMULA		

7,

)			
10 – 150 mg	50 mg	200 – 3000 mg	1000 mg
25 – 150 mg	50 mg	0,5-39	1000 mg
0,03 - 0,15 ml	0,05 ml	0,6 - 3 ml	1 m
0,1 - 0,2 ml	0,15 ml	2-4ml	3 тІ
0,025 - 0,15 ml	0,075 ml	0,5 – 3 ml	1,5 ml
0,1 - 0,6 ml	0,25 ml	2 – 12 ml	5 ml
0,1 - 0,6 ml	0,25 ml	2 – 12 ml	5 ml
0,125 - 0,375 ml	0,25 ml	2,5 – 7,5 ml	5 ml
			500 mg
			500 mg
			500 mg
7.55 - 112,5 mg	75 mg	150 – 2250 mg	1500 mg
			5 ml
		Company of the Compan	1m1
	- 150 mg - 150 mg - 150 mg 1 - 0,2 ml 1 - 0,6 ml 1 - 0,6 ml 2 - 0,375 ml		50 mg 50 mg 0,05 ml 0,25 ml 0,25 ml 0,25 ml

4 ml	4 ml	1 m	15 ml	5 ml	1ml	4 ml	4 ml	5 ml	4 ml	23 ml	1500mg	500 mg	250 mg	250 mg
			1,5 – 22,5 ml							2,3 – 34,5 ml	250 – 1500 mg	100 – 500 mg	250 – 1000 mg	1000 – 2000 mg
a disa dependence or or of the de-			0,75 ml		And the second s					1,15 ml	75 mg	25 mg	12,5 mg	12,5 mg
			0,075 – 1,125 ml				7			0,115 – 1,725 ml	12,5 – 75 mg	5 - 25 mg	12,5 - 50 mg	50 ~ 100 mg
Taraxacum officinale	Tilia platyphyllos	Allium sativum		Achillea millefolium	Viscum album	Taraxacum officinale	Tilia platyphyllos	Valeriana officinalis	Scutellaria lateriflora	La durant de l'activité de l'a	Glucosamine sulphate	Chondroitin sulphate	Curcumin	Salix alba
				FORMULA				The state of the s	PERSONAL PROPERTY AND ADMINISTRATION AND ADMINISTRA					

250 mg	500 mg	250 тд	1500 mg	500 mg	250 mg	250 mg	250 mg	500 mg	50 mg	1 mg	10 mg	2 mg	0,1 mg	500 mg	3813,1 mg
250 – 1500 mg	100 – 1000 mg	10 - 500 mg													381,3 - 5719,65
12,5 mg	25 mg	12,5 mg		The state of the s							The state of the s	Contract of Contra	A SAME AND		190,66 mg
12,5 – 75 mg	5 – 50 тд	0,5 – 25 mg							The state of the s		and the state of t	The state of the s	Transport of the state of the s		19,07 – 285,98
Tanacetum parnethium	Methylsulphonylmethane (MSM)	Boswellía serrata	Glucosamine sulphate	Chondroitin sulphate	Curcumín	Salix alba	Tanacetum parnethium	Methylsulphonylmethane (MSM)	Equisetum arvensis	Copper lysinate	Zinc glycinate	Manganese sulphate	Chelated Selenium	Epigallocatechin gallate (EGCg)	
			FORMULA				HIDOGRAM AND						000,000,000		

	1500 mg	500 mg	250 mg	250 mg	500 mg	500 mg	200 mg	60 mg	3760 mg	500 mg	3.9	3 0	3 g	3.9	3.9
mg						A COLUMN TO THE			376 – 5640 mg	100 –2500 mg	1,59-159	1,59-159	1,5g-15g	1,5 g - 15 g	1,59-159
					And the second s				188 mg	25 mg	150 mg	150 mg	150 mg	150 mg	150 mg
mg				THE PARTY OF THE P	The state of the s				18,8 – 282 mg	5 – 125 mg	75 – 750 mg	75 - 750 mg	75 – 750 mg	75 – 750 тд	75 – 750 mg
	Glucosamine sulphate	Chondroitin sulphate	Curcumin	Boswellia serrata	Epigallocatechin gallate (EGCg)	Methylsulphonylmethane (MSM)	Epigallocatechin (EGC)	Pycnogenol		Epigallocatechin gallate (EGCg)	Epicatechin gallate (ECG)	Epigallocatechin (EGC)	Gallocatechin gallate (GCG)	Gallocatechin (GC)	Epicatechin (EC)
	FORMULA						THE PLANTAGE AND ADDRESS AND A								

3 g	500 mg	3.9	500 mg	3000 mg	3000 mg	3000 mg	100 mg	250 mg	9850 mg		120 mg		300 mg	200 mg		6 тд	120 mg	
1,5 g - 15 g	100 -2500 mg	1,5g-15g		en e					985 - 14775 mg		10 -240 mg		100 - 600 mg	100 - 400 mg	:	1,5 – 6 mg		
150 mg	25 mg	150 mg		The second state of the se					492,5 mg		в тв		15 mg	10 mg		0,3 mg		
75 – 750 mg	5 – 125 mg	75 – 750 mg		TOTAL					49,25 - 738,75	mg	0,5 - 12 mg		5 – 30 тд	5 - 20 mg	MATERIA SECURITARIO	0,075 – 0,3 mg		
Catechin (C)	Epigallocatechin-3-gallate	Epicatechin-3-gallate	Epigallocatechin gallate (EGCg)	Epicatechín (EC)	Epicatechin gallate (ECG)	Epigalloca(echin (EGC)	d-alpha tocopheryl acetate	Ascorbic acid			Gingko biloba	(Standard extract)	Hydrocotyle asiatica	Dimethylaminoethanol Bitartrate	(DMAE)	Rivastigamine	Gingko biloba	(Standard extract)
			FORMULA	THE PROPERTY OF THE PROPERTY O				2012100								THE PARTY OF THE P	FORMULA	

300 mg	200 mg	100 mcg	20 mg	20 mg	20 mg	20 mg	50 mg	750,1 mg	200 mg	4 ml	4 ml	6 ml	3 ml	4 ml
, joboveni ,								75,1 - 1125,15	0,1g - 2g	2 – 12 ml	2 – 12 ml	2 - 12 ml		
American contract the state of								37,5 mg	10 mg	0,2 ml	0,2 ml	0,2 ml		
								3,76 – 56,26 тд	5 – 100 mg	0,1 - 0,6 ml	0,1 - 0,6 ml	0,1 - 0,6 ml		
Hydrocotyle asiatica	Dimethylaminoethanol Bitartrate (DMAE)	Chromium GTF	Thiamine hydrochloride	Riboflavin	Nicotinamide or Niacinamide	Calcium d-Pantothenate	Phosphatidyl Choline		Trigonella foenum-graecum	Oplopanax horridum	Phaseolus vulgaris	Vaccinium myrtillus	Trigonella foenum-graecum	Oplopanax horridum
	The state of the s												FORMULA	

4 ml	6 ml	17 ml	3000 mg	1000 mg	1,5 g	3000 mg	5 g	1,59	3000 mg	3000 mg	1500 mg	7,5 mg	2.9	3000 mg
		1,7 – 25,5 ml	50 - 3000 mg	500 – 1000 mg	0,25 - 30 g	250 – 3000 mg	0,25 - 30 g	1-29				0,75 - 11,25 g		
And Annual Annua		0,85 ml	150 mg	50 mg	75 тв	150 mg	250 mg	75 mg		Annual and the second s		0,38 g		
100000000000000000000000000000000000000		0,085 ~ 1,275 ml	2,5 - 150 mg	25 – 50 mg	12,5 – 1500 тд	12,5 – 150 mg	12,5 – 1500 mg	50 – 100 mg		The state of the s		0,038 – 0,56 g		
Phaseolus vulgaris	Vaccinium myrtillus		Echinacea purpurea	Olea europea extract Containing 12% Oleuropein	Astragalus mebricanaceus root	Hydrastis canadensis root	Allium sativa	Calendula officianalis	Echinacea purpurea	Hydrastis canadensis root	Astragalus mebricanaceus root		Sambucus canadensis	Echinacea purpurea
									FORMULA				FORMULA	

3000 mg	5 g	13g	750 mg	150 mg	750 mg	2500 mg	4150 mg	6 ml	6 ml	5 9	3,75 mg	90 mg	1500 mg	1,5 g	1595,25 mg
and managed and the same and th		1,3 – 19,5 g					415 – 6225 mg	2 –12 ml	2 –12 ml	2 - 12 g				***************************************	159,53
		0,65 g					207,5 mg	0,3 ml	0,3 ml	0,25 g					79,76 mg
		0,065 - 0,975 g					20,75 - 311,25	mg 0,1 - 0,6 ml	0,1 - 0,6 ml	0,1-0,69					7,98 – 119,64
Hydrastis canadensis root	Allium sativa		Artemesia annua	Berberine	Grapefruit seed extract	Allium sativa		Sambucus nìgra	Achillea millefolium	Mentha piperita	Triprolidine HCI	Pseudoephedrine HCI	Ascorbic acid	Echinacea purpurea	
	Company - Assessment of the company		FORMULA				A SALAMAN AND AND AND AND AND AND AND AND AND A				FORMULA				

	500 mg	100 mg	0,2 mg	500 mg	1000 mg	50 mg	2150.2 mg	5 ml	4 ml	E E	5 ml	4 ml	4 ml	5 ml	1 m
2392,88 mg	10 – 5000 mg	1 – 1500 mg	0,01 - 0,3 mg	10 – 5000 mg	100 – 3000 mg	10 – 150 mg	430 – 2800 mg	2 - 15 ml	2 – 12 ml	0,25 – 3 ml	2 – 12 ml	2 - 12 ml	1 - 12 ml	2 - 15 ml	0,5 – 3 ml
							107,51 mg	0,25 ml	0,2 ml	0,05 ml	0,25 ml	0,2 ml	0,2 ml	0,25 ml	0,05 ml
mg							21,5 - 140 mg	0,1 - 0,75 ml	0,1 - 0,6 ml	0,0125 - 0,15 ml	0,1 ~ 0,6 ml	0,1 - 0,6 ml	0,05 – 0,6 ml	0,1 - 0,75 ml	0,025 – 0,15 ml
	Lecithin	Nicotinic acid	Chromium polynicotinate	Allium sativa	Dioscorea villosa	DHEA		Althea officinalis	Angelica archangelica	Cephaelis ipecacuanha	Plantago lanceolata	Thymus vulgaris	Salvia officinalis	Commiphora myrrha	Drosera spp.
	FORMULA														

5 ml	4 ml	4 ml	13 ml	5 ml	5 ml	1 ml	3 ml	14 ml	2000 mg	300 mg		2 ml	5 ml	3 m
			1,3 – 19,5 ml			And the state of t		1,4 - 21 ml	500 – 3000 mg	100 – 700 mg		0,5 - 3 ml	2 - 10ml/ 2	hours 1 – 5 ml
			0,65 ml					0,7 ml	100 mg	15 mg		0,1 ml	0,25 ml	0,15 mľ
			0,065 – 0,975 ml					0,07 – 1,05 ml	25 – 150 mg	5 – 35 mg		0,025 - 0,15 ml	0,1-0,5 ml	0,05 - 0,25 ml
Althea officinalis	Thymus vulgaris	Salvia officinalis		Plantago fanceolata	Commiphora myrrha	Drosera spp.	Ephedra (Ma Huang 1:4 Ø)		Humulus lupulus	Piper methysticum	Standardized Extract (30% - 70% kavalactones)	Passiflora incarnata	Valeriana species	Avena sativa
FORMULA				FORMULA								and the state of t		

250 mg	350 mg	250 mg	500 mg	500 mg	3 mg	1853 mg		300 mg			1000 mg	1500 mg	2800 mg	4 ml	1,5 g	4 ml
	and the state of t					185,3 – 2779,5	mg						280 – 4200 mg	2 – 12 ml	0,5-39	
						92,65 mg		٠					140 mg	0,2 ml	0,075 g	
						9,27 - 138,98	mg						14 – 210 mg	0,1 - 0,6 ml	0,025 - 0,15 g	
Humulus Iupulus	Piper methysticum	Passiflora incarnata	Valeriana species	Avena sativa	Melatonin			Piper methysticum	Standardized Extract (30% - 70%	kavalactones)	Valerian	gamma-Aminobutyric Acid		Turnera diffusa	Serenoa serrulata	Turnera diffusa
FORMULA		*						FORMULA					The second secon			FORMULA

5 ml	3 ml	12 ml	750 mg	500 mg	1000 mg	600 mg	200 mg	500 mg	3.9	750 mg	500 mg	100 mg	250 mg	500 mg
		1,2 – 18 ml	10 – 3000 mg	10 – 2000 mg	10 – 4000 mg	10 – 1000 mg	50 - 200 mg	10 ~ 1000 mg	0,5-4,59					
		0,6 ml	37,5 mg	25 mg	50 mg	30 mg	10 mg	25 mg	0,15g					
		0,06 ~ 0,9 ml	0,5 – 150 mg	0,5 – 100 тд	0,5 – 200 mg	0,5 – 50 mg	2,5 – 10 mg	0,5 - 50 mg	0,025 - 0,225 g		The state of the s		To the state of th	
Serenoa serrulata	Avena sativa		Panax Ginseng	Panax Quinefollium	Eleutherococcus senticosus	Centella asiatica	Paullina guarana	Schisandra chinesis	Pfaffia paniculata	Panax Ginseng	Centella asiatica	Paullina guarana	Schisandra chinesis	Pfaffia paniculata
and the state of t										FORMULA				

500 mg	2350 mg	100 mg	100 mg	100 mg	100 mg	100 mg	100 mg	100 mg	100 mcg	300 mg	300 mcg	250 mg	250 mg	100 mg
	235 – 3525 mg	1 – 100 mg	1 – 100 mg	1 ~ 100 mg	1 – 100 mg	1 – 100 mg	1 – 100 mg	1 – 100 mg	15 - 1000 mcg	1 – 500 mg	1 – 300 mcg	5 – 500 mg	1 - 1500 mg	1 – 1000 mg
	117,5 mg	5 mg	5 mg	5 mg	5 mg	5 mg	5 mg	5 тд	5 mcg	15 mg	15 mcg	12,5 mg	12,5 mg	5 тд
	. 11,75 – 176,25 mg	0,05 – 5 mg	0,05 – 5 mg	0,05 – 5 тд	0,05 – 5 mg	0,05 – 5 тд	0,05 - 5 mg	0,05 – 5 mg	0,75 – 50 mcg	0,05 – 25 mg	0,05 – 15 mcg	0,25 - 25 mg	0,05 – 750 mg	0,05 – 50 mg
Epigallocatechin gallate (EGCg)		Thiamine hydrochloride	Riboflavin	Nicolinamide or Niacinamide	Nicotinic acid or Niacin	Pantothenic acid	Calcium d-Pantothenate	Pyridoxine hydrochloride	Cyanocobalamin	Pangamic acid	Biotin	Choline	Inositol	Para-amino benzoic acid

100 – 4000 mg	100 – 4000 mg	1,5 mg	10mg		5mg	5mg 50mg	5mg 50mg 15mg	5mg 50mg 15mg	5mg 50mg 15mg	5mg 50mg 15mg 10mg	5mg 50mg 15mg 10mg 50mcg	5mg 50mg 15mg 10mg 50mcg 400 mcg	5mg 50mg 15mg 10mg 400 mcg 100 mcg	5mg 50mg 15mg 10mg 400 mcg 250 mg
50 mg	50 mg													
5 – 200 mg	5 – 200 mg					The state of the s								
Phosphatidyl Choline	Lecithin	Retinol palmitate	Thiamine hydrochloride	Riboflavin		Nicotinamide or Niacinamide	Nicotinamide or Niacinamide Pantothenic acid	Nicotinamide or Niacinamide Pantothenic acid Calcium d-Pantothenate	Nicotinamide or Niacinamide Pantothenic acid Calcium d-Pantothenate Pyridoxine hydrochloride	Nicotinamide or Niacinamide Pantothenic acid Calcium d-Pantothenate Pyridoxine hydrochloride Cyanocobalamin	Nicotinamide or Niacinamide Pantothenic acid Calcium d-Pantothenate Pyridoxine hydrochloride Cyanocobalamin Folic acid or Folacin	Nicotinamide or Niacinamide Pantothenic acid Calcium d-Pantothenate Pyridoxine hydrochloride Cyanocobalamin Eolic acid or Folacin Biotin	Nicotinamide or Niacinamide Pantothenic acid Calcium d-Pantothenate Pyridoxine hydrochloride Cyanocobalamin Eolic acid or Folacin Biotin Choline	Nicotinamide or Niacinamide Pantothenic acid Calcium d-Pantothenate Pyridoxine hydrochloride Cyanocobalamin Eolic acid or Folacin Biotin Choline Inositol
		FORMULA		And the Advisor dates										

1000mg	5 тед	2,5 mcg	1707.06 mg	500 mg	300 mg	2700 mg	3500 mg	500 mg	80 mg	2700 mg	3280 mg	500 mg	1000 mg	2700 mg
			170,70	2560.59 mg			700 – 4550 mg				650 – 4260 mg			
			85,35 mg				175 mg				164 mg			
			8,54 128,03				35 – 227,5 mg				32,5 - 213 mg			
Ascorbic acid	Cholecalciferol	d-alpha Tocopheryl acetate		Epigallocatechin gallate (EGCg)	Endostatin	epicatechin gallate (ECG)		Epigallocatechin gallate (EGCg)	Lovastatin	epicatechin gallate (ECG)		Epigallocatechin gallate (EGCg)	Lodine XL	epicatechin gallate (ECG)
				FORMULA				FORMULA				FORMULA		

50 mg 4200 mg	500 mg	750 mg	3000 mg	30 mg 4250 mg	500 mg	20 mg	3000 mg	00 mg 4250 mg	500 mg	0,2 mg	10 mg	3000 mg	10 mg 3510,2 mg
840 - 5460 mg				850 - 5500 mg				850 – 5500 mg					700 – 4560 mg
210 mg			The state of the s	212,5 mg				212,5 mg					175,51 mg
42 - 273 mg		TREATMENT OF THE PRINCIPLE OF THE PRINCI	and the state of t	42,5 - 275 mg				42,5 – 275 mg					35 – 228 mg
	Epigallocatechin gallate (EGCg)	Curcumin	epicatechin gallate (ECG)		Epigallocatechin gallate (EGCg)	Tamoxifen	epicatechin gallate (ECG)		Epigallocatechin gallate (EGCg)	Selenium	Lycopene	epicatechin gallate (ECG)	The state of the s
	FORMULA				FORMULA	The state of the s			FORMULA	- The control of the			

TABLE 2 - UNIT DOSAGE

ш												
۵	250 mg	0,5g	200 mg	25 mg	250 mg	250 mg	5 mg	500 mg	250 mg	250 mg	500 mg	5 mg
O	0,3-49	0,5-4g	0,6-1,2g	50 – 150 mg	500 –1500 mg	250 – 750 mg	10 – 60 тд	500 – 1500 mg	1000 – 2000 mg	250 – 1500 mg	2000 mg	20 mg
В								, motories				
۲												
Name / Substance / Compound / Active Ingredient	Acetylsalycilic acid	Paracetamol	Ibuprofen	Indomethacin	Mefenamic acid	Naproxen	Codeine Phosphate	dl-Phenylalanine	Salix alba	Tanacetum pamethium	Paracetamol	Codeine Phosphate

	-	1.31h	бш с/ - ∩!	52 mg	
	Nortriptyline HCI	The state of the s	25 – 100 mg	25 mg	
	Imipramine HCI		75 –150 mg	25 mg	
	Dothepin HCI		25 – 75 mg	25 mg	
	Trimipramine HCI		50 – 100 mg	50 mg	
	Mianserin HCl		30 – 90 mg	10 mg	
	Fluoxetine HCI		20 - 80 mg	20 mg	The second secon
	Paroxetine HCI		10 – 50 mg	10 mg	
	Citalopram hydrobromide		20 mg	20 mg	
April 1 de la constantina	Sertraline HCI		50 – 200 mg	50 mg	
	Verilafaxine HCI		37,5 – 75 mg	37,5 mg	
FORMULA	Hypericum perfoliatum (as standarized extract of 0.3%		50 - 900 mg	300 mg	
	Hypericin)				
	5-Hydroxy-tryptophan		10 - 150 mg	50 mg	1
	(as seed extract of Griffonia				
	simplificolia)				
			A CONTRACTOR OF THE CONTRACTOR	350 mg	35 - 1050 ma

				130 – 3900 mg						130 - 5200 mg					·
300 mg			1000 mg	1300 mg	250 mg	50 mg			1000 mg	300 mg	5 mg	1 mg	5 тд	1 mg	0,1 mg
50 - 900 mg			200 – 3000 mg		50 – 1000 mg	100 mg			0,5-3g	And the state of t	10 – 100 mg	2 – 8 mg	25 -100mg	5 – 20 mg	0,5 – 4,5 mg
														The state of the s	
				A LA											
Hypericum perfoliatum	(as standarized extract of 0,3%	Hypericin)	Eleutherococcus senticosus		Rhodiola rosea	5-Hydroxy-fryptophan	(as seed extract of Griffonia	simplificolia)	Panax Ginseng		Promethazine HCI	Dexchlorpheneramine mal.	Mepyramine maleate	Prednisone	Betamethasone
FORMULA				e e e e e e e e e e e e e e e e e e e	FORMULA										

Propanolol HCI10 - 480 mg10 mg

					The state of the s									
50 mg	80 mg	10 mg	2,5 mg	1 mg	20 mg	5 mg	5 mg	100 mg	80 mg	250 mg	200 mcg	2,5 mg	0,5 mg	250 mg
50 - 100 mg	160 –320 тд	25 – 150 mg	2,5 – 20 mg	5 - 20 mg	40 - 360 mg	20 – 40 mg	2,5 – 15 mg	100 – 500 mg	80 320 mg	0,59-39	200 – 1600 mcg	2,5 mg – 15 mg	0,5 mg - 1,5 mg	750 – 1500 mg
Atenelol HCl	Sotalol Hcl	Captopril	Enalaprii maleate	Losarian	Verapamil HCI	Nifedipine	Glibenclamide	Chlorpropramide	Gliclazide	Metformin HCI	Salbutamol	Fenoterol HBr	Hexoprenaline	Amoxicillin trihydrate
	and the second s													

			The same of the sa									
250 mg	500 mg	250 тд	250 mg	375 mg	100 mg	250 mg	200 mg	25 mg	250 mg	250 mg	250 mg	
1000 – 2000 mg	500 - 2000 mg	1000 – 2000 mg	1000 – 4000 mg	750 - 1500 mg	200 – 400 mg	1000 – 4000 mg	0,6 - 1,2 g	50 – 150 mg	500 - 1500 mg	250 ~ 750 mg	0,3-49	

Ampicillin trihydrate	Cloxacillin sodium	Cephradine	Cephalexin monohydrate	Cefaclor	Cefpodoxime	Erythromycin stearate	Ibuprofen	Indomethacin	Mefenamic acid	Naproxen	Acetylsalycillic acid	
					THE RESIDENCE AND ADDRESS OF THE PARTY OF TH	And the state of t	t role to					A THE STATE OF THE

CLAIMS:

5

10

15

- 1. A smoker's requisite which embodies a substance selected from pharmaceutical products, food supplements, natural products and combinations thereof, the substance being embodied in the requisite such that, when the requisite is lit and smoked by a smoker, a quantity of the substance is ingested by the smoker.
- 2. A smoker's requisite as claimed in Claim 1, which includes a component selected from one or more of tobacco, paper, a filter and a carrier, the substance being embodied in one or more of the tobacco, paper, filter or carrier.
- 3. A smoker's requisite as claimed in Claim 1, which includes a filter and in which the filter is formed from the substance.
 - 4. A smoker's requisite as claimed in Claim 1, in which the substance is selected from flavanols, anelgesics, anti-pyretics, anti-carcinogenic and chemo preventive agents, anxiolytics, angiogenisis inhibitors, anti-aging substances, antibiotics, antihistimines and anti-allergenics, anti-hypertensive agents, anti-inflammatories, memory and brain function treatment agents, cardiovascular and circulatory agents, diabetes treatments, hypocolesterolemics, immune system enhancers, immunizing agents, minerals, respiratory agents, sedatives, anti-stress agents, aphrodisiacs, sexual disfunction agents, enhancement drugs, tonics, stimulants and vitamins, nitrosoureas, tryptamine derivatives, proteins, steroids, vitamins and provitamins, statins, sulphonamides, substituted indoles, substituted imidazoles, and metal-containing compounds, drug substances, anti-depressants, immunosuppressants, hormones, antibiotics, phytochemicals, and mixtures of any two or more thereof.
- 5. A smoker's requisite as claimed in Claim 1, in which the natural product is selected from catechin, gallic acid, epigallocatechin gallate, epigallocatechin, epicatechin, epicatechin-3-gallate, epicatechin gallate and epigallocatechin-3-gallate.

 i_1

- 6. A smoker's requisite as claimed in Claim 4, in which the tryptamine derivative is selected from serotonin and melatonin.
- 7. A smoker's requisite as claimed in Claim 4, in which the protein is selected from endostatin and angiostatin.
- 5 8. A smoker's requisite as claimed in Claim 4, in which the steroid is a steroidal anti-inflammatory compound.
 - 9. A smoker's requisite as claimed in Claim 4, in which the natural product is selected from tocopherol, alpha-tocopherol, beta-carotene, retinoic acid and ascorbic acid.
- 10 10. A smoker's requisite as claimed in Claim 4,in which the statins and compactins are selected from lovastatin, simvastatin and pravastatin.
 - 11. A smoker's requisite as claimed in Claim 4, in which the sulphonamide is nimesulide.
- 12. A smoker's requisite as claimed in Claim 4, in which the substituted indole is Lodine (etodolac).
 - 13. A smoker's requisite as claimed in Claim 4, in which the substituted imidazole is dacarbazine.
 - 14. A smoker's requisite as claimed in Claim 4, in which the organometallic compound or the metal-containing compound is selected from cisplatin and selenium compounds.

20

15. A smoker's requisite as claimed in Claim 1, in which the natural product is selected from lycopene, caffeine, prenyl flavonoids, camellia sinensis and rosemary.

A smoker's requisite as claimed in Claim 1, in which the natural product is a natural anti-carcinogen of the type found in foods selected from alfalfa, onions, spinach, broccoli, kale, garlic, red bell peppers and beets, fruits, red grapes, white grapes, oranges, strawberries, kiwi fruit, grapefruit, pink grapefruit and their seeds, tomato and apple and beverages selected from teas from camelia sinensis, apple juice, grape juice, red wine, tomato, orange, and cocoa.

- 17. A smoker's requisite as claimed in Claim 1, in which the natural product is a plant substance selected from Echinacea, ambrosia, marijuana/cannabis/hemp and alfalfa.
- 18. A smoker's requisite as claimed in Claim 1, in which the pharmaceutical product is selected from anti-carcinogenic substances, tofenacin, traodone, viloxazine, interferon, thalidomide, Col-3, tamoxifen, thymidylate synthase inhibitors, COX-2 inhibitors, celebrex, rofecoxib (vioxx), imatinib mesylate (gleevec), (STI 571), cyproheptadine aspirin and paracetamol.
- 19. A smoker's requisite as claimed in Claim 4, in which the anti-depressant is selected from monoamine oxidase inhibitors selected from the hydrazine derivatives, isocarboxazid, phenelzine, nialamide, iproniazid and mebanzine and the non-hydrazine monoamine oxidase inhibitors selected from pargyline, the tricyclic anti-depressants dibenzazepine, the zocyclohepetene derivatives amitriptyline, butriptyline, desipramine, clomipramine, protriptyline, nortriptyline, opipramol, trimipramine iprindole and the tetracyclics maprotiline and mianserin.
 - 20. A smoker's requisite as claimed in Claim 15, in which the prenyl flavonoid is selected from prenylchalcones, prenylflavonones, 2-hydroxy-2-methylbut-3-ene and xanthohumol.
- 25 21. A smoker's requisite as claimed in Claim 1, in which the food supplement is selected from a calcium supplement, a tonic and a stimulant.

WO 02/080708 PCT/IB02/01112

52

- 22. A smoker's requisite as claimed in Claim 1, in which the natural product is a natural anti-carcinogen.
- 5 catsclaw, olive leaf (as well as the extract of olive leaf and olive leaf concentrate), pau-d'arco, mistletoe (also sold as iscar and iscador) or cartilage including shark cartilage.
 - 23. A carrier which is shaped and dimensioned to be received in a smoker's requisite or a smoking accessory selected from cigarettes, cigars, cigarette holders, filters, cigar holders and pipes and which incorporates a substance selected from pharmaceutical products, food supplements, natural products and combinations thereof, the substance being incorporated in the requisite such that, when the requisite is lit and smoked by a smoker, a quantity of the substance is ingested by the smoker.

10

- 15 24. A carrier as claimed in Claim 23, which is in the form of a package, cartridge, filter, membrane, pill, sponge, matrix, tablet or string.
 - 25. A smoking accessory selected from cigarette holders, cigar holders and detachable filters which incorporates a substance selected from pharmaceutical products, food supplements, natural products and combinations thereof.

٦,

- 26. A method of making a smoker's requisite which embodies a substance selected from pharmaceutical products, food supplements, natural products and combinations thereof, which includes combining a component of a smoker's requisite with the substance and using the component to make the requisite.
- 27. A method of administering to a person a substance selected from pharmaceutical products, food supplements, natural products and combinations thereof which includes the step of incorporating the substance in a smoker's requisite as

WO 02/080708 PCT/IB02/01112

53

claimed in Claim 1,so that, when the smoker's requisite is smoked by a person, an amount of the substance is ingested by the person during smoking.

28. A method as claimed in Claim 27, which includes the steps of combining the substance with a component of a smoker's requisite, and using the component in the manufacture of a smokers requisite.

5

- 29. A method as claimed in Claim 28, in which the component is selected from tobacco, cigar leaves, cigarette paper and cigarette filters
- 30. A method of administering to a person a substance selected from pharmaceutical products, food supplements, natural products and combinations thereof which includes the step of incorporating the substance in a smoking accessory as claimed in Claim 25, so that, when the smoking accessory is used together with a smoker's requisite selected from cigarettes, cigars, pipes and cheroots, an amount of the substance is ingested by the person during smoking.
- 31. A method of making a smoker's requisite which embodies a substance selected from pharmaceutical products, food supplements, natural products and combinations thereof, which includes incorporating a carrier which carries the substance in the smoker's requisite so that when the requisite is lit and smoked by a smoker, a quantity of the substance is ingested by the smoker.
- 32. A smoker's requisite as claimed in Claim 1, in which the substance is selected from the substances set out in Table 1 and Table 2.
 - 33. A smoker's requisite as claimed in Claim 32, in which the quantity of the substance embodied in the requisite is between the lower value in column A and the higher value in column C of Table 1 or the amount in column C of Table 2.
- 34. A smoker's requisite as claimed in Claim 33, in which the quantity of the substance embodied in the requisite is as set out in column A of Table 1.

WO 02/080708 PCT/IB02/01112

54

- 35. A smoker's requisite as claimed in Claim 34, in which the quantity of the substance is as set out in column B of Table 1 or column D of Table 2.
- 36. A smoker's requisite as claimed in Claim 1, in which the quantity of the substance is between the lower value in column C of Table 2 and the higher value in column E of Table 2.

(19) World Intellectual Property Organization

International Bureau





(43) International Publication Date 17 October 2002 (17.10.2002)

(10) International Publication Number WO 2002/080708 A3

(51) International Patent Classification7: 15/16, A24D 3/14, 3/06, 3/16

A24B 15/28,

(21) International Application Number:

PCT/IB2002/001112

(22) International Filing Date: 9 April 2002 (09.04.2002)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2001/2893 9 April 2001 (09.04.2001) ZA 2001/4060 18 May 2001 (18.05.2001)

(71) Applicant and

(72) Inventor: ENSLIN, George, Frederick [ZA/ZA]; 6 Waldorf Drive, Centurion Golf Estate, 0002 Centurion (ZA).

(74) Agent: FORBES, Craig, Paul; Adams & Adams, Adams & Adams Place, 1140 Prospect Street, Hatfield, PO Box 1014, 0001 Pretoria (ZA).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE. TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

with international search report

(88) Date of publication of the international search report: 4 March 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: A SMOKER'S REQUISITE

(57) Abstract: A smoker's requisite embodies a substance selected from pharmaceutical products, food supplements, natural products and combinations thereof. The substance is embodied in the requisite such that, when the requisite is lit and smoked by a smoker, a quantity of the substance is ingested by the smoker.

Fax: (+31-70) 340-3016

International Application No

PCT/IB 02/01112 A. CLASSIFICATION OF SUBJECT MATTER 1PC 7 A24B15/28 A24B15/16 A24D3/14 A24D3/06 A24D3/16 According to International Patent Classification (IPC) or to both national classification and IPC **B. FIELDS SEARCHED** Minimum documentation searched (classification system followed by classification symbols) IPC 7 A24B A24D Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the International search (name of data base and, where practical, search terms used) WPI Data, EPO-Internal, BIOSIS C. DOCUMENTS CONSIDERED TO BE RELEVANT Category ° Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. χ DATABASE WPI 1-5. 24-36 Section Ch, Week 199324 Derwent Publications Ltd., London, GB; Class D18, AN 1993-190688 XP002223128 & JP 05 115273 A (UENOYA BIKOEN YG), 14 May 1993 (1993-05-14) abstract US 5 829 449 A (HERSH REBECCA ET AL) χ 1-5. 3 November 1998 (1998-11-03) 23-36 column 12, line 55 -column 13, line 67; claims US 6 082 370 A (RUSSO JOSEPH D) Χ 1-4. 4 July 2000 (2000-07-04) 23-36 claims -/--Further documents are listed in the continuation of box C. Patent family members are listed in annex. X Special categories of cited documents: "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "A" document defining the general state of the last which is not considered to be of particular relevance "E" earlier document but published on or after the international "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "&" document member of the same patent family Date of the actual completion of the international search Date of mailing of the international search report 12 03 2003 6 December 2002 Authorized officer Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 Nt. - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, LEPRETRE, F

International Application No
PCT/IB 02/01112

		PCT/IB 02/01112
	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category ^o	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 944 026 A (WILDENAU WOLFGANG ET AL) 31 August 1999 (1999-08-31) claims	1-4, 23-36
X	US 5 016 655 A (WADDELL WILLIAM J ET AL) 21 May 1991 (1991-05-21) claims	1-4, 23-36
X	US 4 124 033 A (ZIZKA JAROSLAV ET AL) 7 November 1978 (1978-11-07) claims	1-4, 23-36

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-4 (partially) 5, 23-36 (partially)

A smoker's requisite which embodies a substance such that when the requisite is lit and smoked, a quantity of the substance is ingested by the smoker, the substance being catechin, gallic acid, epigallocatechin, epicatechin or epicatechin gallate and derivatives thereof.

2. Claims: 1-4 (partially), 6, 25-36 (partially)

A smoker's requisite which embodies a substance such that when the requisite is lit and smoked, a quantity of the substance is ingested by the smoker, the substance being a tryptamine derivative selected from serotonin and melatonin.

3. Claims: 1-4 (partially), 7,10, 23-36 (partially)

A smoker's requisite which embodies a substance such that when the requisite is lit and smoked, a quantity of the substance is ingested by the smoker, the substance being a statin or a protein selected from endostatin and angiostatin.

4. Claims: 1-4 (partially), 8, 23-36 (parrtially)

A smoker's requisite which embodies a substance such that when the requisite is lit and smoked, a quantity of the substance is ingested by the smoker, the substance being a steroid.

5. Claims: 1-4 (partially), 9, 23-36 (partially)

A smoker's requisite which embodies a substance such that when the requisite is lit and smoked, a quantity of the substance is ingested by the smoker, the substance being a natural product selected from tocopherol, alpha-tocopherol, beta carotene, retinoic acid and ascorbic acid.

6. Claims: 1-4 (partially), 11, 23-36 (partially)

A smoker's requisite which embodies a substance such that when the requisite is lit and smoked, a quantity of the substance is ingested by the smoker, the substance being a sulphonamide.

7. Claims: 1-4 (partially), 12, 23-36 (partially)

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

A smoker's requisite which embodies a substance such that when the requisite is lit and smoked, a quantity of the substance is ingested by the smoker, the substance being substituted indole.

8. Claims: 1-4 (partially), 13, 23-36 (partially)

A smoker's requisite which embodies a substance such that when the requisite is lit and smoked, a quantity of the substance is ingested by the smoker, the substance being a substituted imidazole.

9. Claims: 1-4 (partially), 14, 23-36 (partially)

A smoker's requisite which embodies a substance such that when the requisite is lit and smoked, a quantity of the substance is ingested by the smoker, the substance being an organometallic compound.

10. Claims: 1-4 (partially), 15,20, 23-36 (partially)

A smoker's requisite which embodies a substance such that when the requisite is lit and smoked, a quantity of the substance is ingested by the smoker, the substance being selected from lycopene, caffeine, prenyl flavonoid, camellia sinensis and rosemary.

11. Claims: 1-4 (partially), 16, 23-36 (partially)

A smoker's requisite which embodies a substance such that when the requisite is lit and smoked, a quantity of the substance is ingested by the smoker, the substance being a natural anti-carcinogen of the type found in foods.

12. Claims: 1-4 (partially), 17, 23-36 (partially)

A smoker's requisite which embodies a substance such that when the requisite is lit and smoked, a quantity of the substance is ingested by the smoker, the substance being a plant substance selected from Echinacea, ambrosia, marijuana/cannabis/hemp and alfalfa.

13. Claims: 1-4 (partially), 18, 23-36 (partially)

A smoker's requisite which embodies a substance such that when the requisite is lit and smoked, a quantity of the substance is ingested by the smoker, the substance being a pharmaceutical product according to claim 18.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

14. Claims: 1-4 (partially), 19, 23-36 (partially)

A smoker's requisite which embodies a substance such that when the requisite is lit and smoked, a quantity of the substance is ingested by the smoker, the substance being an anti-depressant in accordance with claim 19.

15. Claims: 1-4 (partially), 21, 23-36 (partially)

A smoker's requisite which embodies a substance such that when the requisite is lit and smoked, a quantity of the substance is ingested by the smoker, the substance being a food supplement selected from calcium supplement, a tonic and a stimulant.

16. Claims: 1-4 (partially), 22, 23-36 (partially)

A smoker's requisite which embodies a substance such that when the requisite is lit and smoked, a quantity of the substance is ingested by the smoker, the substance being a natural anti-carcinogen in accordance with claim 22.

PCT/IB 02/01112

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
JP 5115273 A	14-05-1993	NONE	
US 5829449 A	03-11-1998	AU 743757 AU 8784098 BR 9812479 CA 2303863 CN 1280463 EP 1014812 JP 2001516771 WO 9915035 US 2002179103 US 6138683 US 6415798 US 2002117180	A 12-04-1999 A 13-02-2002 A1 01-04-1999 T 17-01-2001 A1 05-07-2000 T 02-10-2001 A1 01-04-1999 A1 05-12-2002 A 31-10-2000 B1 09-07-2002
US 6082370 A	04-07-2000	AU 752456 AU 2656099 BR 9907793 CA 2320198 CN 1292647 CZ 20002901 EA 2711 EP 1054603 JP 2002501768 US 6079418 WO 9939595 ZA 9901030	A 23-08-1999 A 17-10-2000 A1 12-08-1999 T 25-04-2001 A3 15-08-2001 B1 29-08-2002 A1 29-11-2000 T 22-01-2002 A 27-06-2000 A1 12-08-1999
US 5944026 A	31-08-1999	BG 63420 BG 100927 CA 2184592 CN 1148324 CZ 9602944 DE 59508825 DK 756461 EE 9600149 WO 9528098 EP 0756461 ES 2151598 GR 3035240 HK 1012873 HU 76247 JP 10503082 LV 11721 LV 11721 MD 1976 PL 316760	T 15-11-2000 B1 31-01-2002 A 31-07-1997 A1 26-10-1995 A 23-04-1997 D1 07-12-2000 T3 18-12-2000 A 15-04-1997 A1 26-10-1995 A1 05-02-1997 T3 01-01-2001 T3 30-04-2001 A1 12-04-2001 A2 28-07-1997 T 24-03-1998 A 20-04-1997 B 20-12-1997 B 20-12-1997 B 31-08-2002 A1 03-02-1997 T 30-04-2001 B1 30-09-2002 C1 20-12-1999 T1 30-04-2001
US 5016655 A	21-05-1991	US 4967772 US 4966169 AU 3055989	A 30-10-1990

PCT/IB 02/01112

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
US 5016655	Α		MO	8906912 A1	10-08-1989
US 4124033	А	07-11-1978	CS CH DD DE SE	165807 B1 543245 A 101283 A5 2257766 A1 383955 B	22-12-1975 31-10-1973 05-11-1973 13-03-1975 12-04-1976